Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | ARG1 | P05089 | 2/20 | 0.55 |
| ▸ | ARG2 | P78540 | 2/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | ODC1 | P11926 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8351006 | 0.88 | SMN1; SMN2 (0.69) | SMN1; SMN2HIF1AARG1ARG2SLC6A2 | |
| SCHEMBL25578512 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2HIF1AARG1ARG2SLC6A2 | |
| SCHEMBL4245719 | 0.85 | BLM (0.59) | SMN1; SMN2HIF1AARG1ARG2ODC1 | |
| SCHEMBL22033172 | 0.85 | BLM (0.59) | SMN1; SMN2HIF1AARG1ARG2ODC1 | |
| SCHEMBL4245716 | 0.85 | BLM (0.59) | SMN1; SMN2HIF1AARG1ARG2ODC1 | |
| SCHEMBL12583604 | 0.85 | HIF1A (0.60) | SMN1; SMN2HIF1AARG1ARG2SLC6A2 | |
| SCHEMBL1842425 | 0.85 | HIF1A (0.60) | SMN1; SMN2HIF1AARG1ARG2SLC6A2 | |
| SCHEMBL11265744 | 0.85 | HIF1A (0.60) | SMN1; SMN2HIF1AARG1ARG2SLC6A2 | |
| SCHEMBL2896017 | 0.83 | GRM2 (0.45) | SMN1; SMN2HIF1AARG1ARG2TAAR1 | |
| SCHEMBL366770 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2HIF1AARG1ARG2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005030735-A1 | TRIAZINES DERIVATIVES AS CELL ADHESION INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2005-04-07 | — | — | WO | claimed |
| US-12162902-B2 | Decarboxylase inhibitors for treating Parkinson's disease | SAIL BIOMEDICINES (US) | 2024-12-10 | — | — | US | disclosed |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | SENDA BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | SENDA BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230174460-A1 | AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-08 | — | — | US | disclosed |
| US-20220048849-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | SENDA BIOSCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220048849-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | SENDA BIOSCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| EP-3891122-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | Senda Biosciences, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| CN-113302176-A | Decarboxylase inhibitors for the treatment of parkinson's disease | 先达生物科技公司 | 2021-08-24 | — | — | CN | disclosed |
| WO-2020118163-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | KINTAI THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020118163-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | KINTAI THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-20150045328-A1 | DISUBSTITUTED ARYL OXY DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. | 2015-02-12 | — | — | US | disclosed |
| EP-1689713-B1 | BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER S DISEASE | MERCK SHARP & DOHME (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-1689713-A4 | BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER S DISEASE | MERCK & CO INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-7354942-B2 | Benzylether and benzylamino beta-secretase inhibitors for the treatment of Alzheimer's disease | MERCK & CO., INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070088165-A1 | preventing the formation of insoluble A beta and arresting the production of A beta; beta-site amyloid precursor protein-cleaving enzyme; 3-[(2-amino-2-methyl-3-phenylpropoxy)methyl]-N-[(1R)-1-(4-fluorophenyl)ethyl]-[methyl(methylsulfonyl)amino]benzamide | MERCK SHARP & DOHME LLC | 2007-04-19 | — | — | US | disclosed |
| EP-1689713-A1 | BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER S DISEASE | Merck & Co., Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| WO-2005051914-A1 | BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045328-A1 | DISUBSTITUTED ARYL OXY DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | S1PR1, S1PR3, S1PR2 | SMN1; SMN2 3562/4885HIF1A 2285/4885ARG1 3016/4885 |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | SMN1; SMN2 57/4885HIF1A 518/4885ARG1 165/4885 |
| US-12162902-B2 | Decarboxylase inhibitors for treating Parkinson's disease | DDC, DDT, DDO | SMN1; SMN2 983/4885HIF1A 4436/4885ARG1 1579/4885 |
| US-20230174460-A1 | AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE | PARK7, SNCA, RHOT2 | SMN1; SMN2 24/4885HIF1A 4527/4885ARG1 3585/4885 |
| US-20070088165-A1 | preventing the formation of insoluble A beta and arresting the production of A beta; beta-site amyloid precursor protein-cleaving enzyme; 3-[(2-amino-2-methyl-3-phenylpropoxy)methyl]-N-[(1R)-1-(4-fluorophenyl)ethyl]-[methyl(methylsulfonyl)amino]benzamide | BACE1, BACE2, APP | SMN1; SMN2 356/4885HIF1A 2734/4885ARG1 1899/4885 |
| US-20220048849-A1 | DECARBOXYLASE INHIBITORS FOR TREATING PARKINSON'S DISEASE | DDC, DDT, DDO | SMN1; SMN2 983/4885HIF1A 4436/4885ARG1 1579/4885 |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | COMT, SNCA, PARK7 | SMN1; SMN2 151/4885HIF1A 3718/4885ARG1 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.